

March 3, 2010

Research Opportunities Compiled by:

**Ohio Supercomputer Center
Janet L. Gregory, Grants Manager
1224 Kinnear Road
Columbus, OH 43212-1163
Phone: 614-292-8492
Fax: 614-688-3184
Email: jgregory@osc.edu**

Opportunity #1

**Office-Wide Broad Agency Announcement Microsystems Technology Office
Department of Defense - DARPA
DARPA-BAA-10-35**

Description: The Microsystems Technology Office's (MTO) mission is to exploit breakthroughs in materials, devices, circuits, and mathematics to develop beyond leading edge Microsystems components with revolutionary performance and functionality to enable new platform capability for the Department of Defense. To execute this mission, MTO supports revolutionary research in electronics, photonics, MEMS, algorithms, and combined Microsystems technology to deliver new capabilities to sense, communicate, energize, actuate, and process data and information for the war fighter. MTO regularly publishes Broad Agency Announcements requesting responses to specific program topics. This announcement seeks revolutionary research ideas for topics not being addressed by ongoing MTO programs or other published BAA solicitations. This BAA is primarily, but not solely, intended for early stage research (Studies) that may lead to larger, focused MTO programs in the future. Studies are defined as single phase efforts of short duration (< 12 months) costing less than \$1,000,000. Whereas proposers are strongly encouraged to submit Studies to this BAA, Multi-Phase Efforts will also be considered. Multi-Phase Efforts are efforts with more than one phase that may span longer than 12 months and that may cost more than \$1,000,000. Multi-Phase Efforts must also cover discernable research topic areas that lead to clearly defined, quantitative technical metrics. See full DARPA-BAA-10-35 attached.

Link to Full Announcement:

<http://www07.grants.gov/search/announce.do;jsessionid=yskPLThYrSd1vPpkR1hGLPzTdyxpZQmr2tByyFVv7xnQkySJD94Z!117535442>

Opportunity #2

**Research in Innovative Approaches to Fusion Energy Sciences
Department of Energy - Chicago Service Center
DE-FOA-0000286**

Description: The Fusion Energy Sciences (FES) Program of the Office of Science (SC), U.S. Department of Energy (DOE), hereby announces its interest in receiving grant applications for innovative approaches to fusion energy sciences. All individuals or groups planning to submit applications for new or renewal funding in Fiscal Year 2011 should submit in response to this FOA.

Link to Full Announcement:

https://www.fedconnect.net/FedConnect/PublicPages/PublicSearch/Public_Opportunities.aspx

Opportunity #3

Agile Delivery of Electrical Power Technology (ADEPT) Department of Energy DE-FOA-0000288

Description: The Advanced Research Projects Agency-Energy (ARPA-E) is a new agency of the Department of Energy. ARPA-E was authorized by the America COMPETES Act (PL 110-69) and charged with the mission to fund projects that will develop transformational technologies that reduce Americas dependence on foreign energy imports; reduce U.S. energy related emissions, including greenhouse gases; improve energy efficiency across all sectors of the U.S. economy; and ensure that the United States maintains its leadership in developing and deploying advanced energy technologies. Initially funded through the American Recovery and Reinvestment Act (PL 111-5), ARPA-E aims to support the development of high risk/high payoff applied science and technology innovations that will have a positive disruptive impact on the energy landscape. In the United States about 40 percent of the primary energy consumed is used to produce electricity. Electricity is projected to supply an increasing share of the world's total energy demand and is the fastest-growing form of end-use energy worldwide. The goal of this Funding Opportunity Announcement (FOA) is to invest in power electronic technologies that can leapfrog over today's approaches and create the technologies to enable a 25-30 percent reduction in electricity consumption (or 12 percent of the total U.S. energy consumption) and significant reductions in cost and form factor for power electronics

Link to Full Announcement:

https://www.fedconnect.net/FedConnect/PublicPages/PublicSearch/Public_Opportunities.aspx

Opportunity #4

Gridscale Rampable Intermittently Dispatchable Storage (GRIDS) Department of Energy DE-FOA-0000290

Description: The Advanced Research Projects Agency-Energy (ARPA-E) is a new agency of the Department of Energy. ARPA-E was authorized by the America COMPETES Act (PL 110-69) and charged with the mission to fund projects that will develop transformational technologies that reduce Americas dependence on foreign energy imports; reduce U.S. energy related emissions, including greenhouse gases; improve energy efficiency across all sectors of the U.S. economy; and ensure that the United States maintains its leadership in developing and deploying advanced energy technologies. Initially funded through the American Recovery and Reinvestment Act (PL 111-5), ARPA-E aims to support the development of high risk/high payoff applied science and technology innovations that will have a positive disruptive impact on the energy landscape. In this program, ARPA-E seeks to develop a new generation of low-cost energy storage technologies for the electricity grid. A key role of energy storage is to transform the grid from a system for delivering electric power where it is needed, to system that flexibility adapts to changes in where electric power is needed. The added dimension of time enables a radical increase in the use of electricity from intermittent renewable resources, such as wind and solar. The goals of this program are targeted to develop innovative energy storage technologies which have the cost and reliability of hydroelectric power, yet have the capacity for deployment in any location. The cost effective grid-scale energy storage technologies developed in this program will lower CO2 emissions from U.S. electricity generation, improve security through enhanced power reliability and establish U.S. leadership in advanced energy storage systems. ARPA-E's objective is to fund high-risk, high-reward research efforts to address emerging grid-scale energy storage needs.

Link to Full Announcement:

https://www.fedconnect.net/FedConnect/PublicPages/PublicSearch/Public_Opportunities.aspx

Opportunity #5

NIJ FY 2010 Fundamental Research to Improve Understanding of the Accuracy, Reliability, and Measurement Validity of Forensic Science Disciplines National Institute of Justice NIJ-2010-2404

Description: NIJ seeks qualified applicants to conduct research to improve the understanding of the accuracy, reliability, and measurement validity of the forensic science disciplines (specific disciplines stated below). In this solicitation, the term "validity" refers to the extent of the truth of an inference based upon scientific measurement. In other words, what is the extent to which relevant scientific evidence supports an inference as being true or correct? This solicitation does not address subjective, qualitative, or legal analyses of validity.

Link to Full Announcement:

<http://www.ncjrs.gov/pdffiles1/nij/sl000909.pdf>

Opportunity #6

ROSES 2010: NPP Science Team for Climate Data Records NASA NNH10ZDA001N-NPP

Description: This NASA Research Announcement (NRA) solicits proposals for supporting basic and applied research and technology across a broad range of Earth and space science program elements relevant to one or more of the following NASA Research Programs: Earth Science, Heliophysics, Planetary Science, and Astrophysics. This ROSES NRA covers all aspects of basic and applied supporting research and technology in space and Earth sciences, including, but not limited to: theory, modeling, and analysis of SMD science data; aircraft, stratospheric balloon, suborbital rocket, and commercial reusable rocket investigations; development of experiment techniques suitable for future SMD space missions; development of concepts for future SMD space missions; development of advanced technologies relevant to SMD missions; development of techniques for and the laboratory analysis of both extraterrestrial samples returned by spacecraft, as well as terrestrial samples that support or otherwise help verify observations from SMD Earth system science missions; determination of atomic and composition parameters needed to analyze space data, as well as returned samples from the Earth or space; Earth surface observations and field campaigns that support SMD science missions; development of integrated Earth system models; development of systems for applying Earth science research data to societal needs; and development of applied information systems applicable to SMD objectives and data. Awards range from under \$100K per year for focused, limited efforts (e.g., data analysis) to more than \$1M per year for extensive activities (e.g., development of science experiment hardware). The funds available for awards in each program element offered in this ROSES NRA range from less than one to several million dollars, which allow selection from a few to as many as several dozen proposals depending on the program objectives and the submission of proposals of merit. Awards will be made as grants, cooperative agreements, contracts, and inter- or intra-agency transfers depending on the nature of the proposing organization and/or program requirements. The typical period of performance for an award is four years, although a few programs may specify shorter or longer (maximum of five years) periods. Organizations of every type, domestic and foreign, Government and private, for profit and not-for-profit, may submit proposals without restriction on number or teaming arrangements. Note that it is NASA policy that all investigations involving non-U.S. organizations will be conducted on the basis of no exchange of funds. Proposal due dates are scheduled starting on April 30, 2010, and continue through April 30, 2011.

Link to Full Announcement:

<http://nspires.nasaprs.com/external/solicitations/summary.do?method=init&solId={9636473D-602B-F49F-ABDC-5A26F36D08CD}&path=open>

Opportunity #7

Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) DHHS – NIH PAR-10-116

Description: The Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences supports broad and fundamental, early-stage graduate research training in the neurosciences via institutional NRSA research training grants (T32) at domestic institutions of higher education. Trainees are supported during years 1 and 2 of their graduate research training when they are typically not committed to a dissertation laboratory. The primary objective is to prepare qualified individuals for careers in neuroscience that have a significant impact on the health-related research needs of the Nation. This Funding Opportunity Announcement (FOA) will utilize the Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) award mechanism.

Link to Full Announcement:

<http://grants.nih.gov/grants/guide/pa-files/PAR-10-116.html>

Opportunity #8

Common Pathogenetic Mechanisms of Lung Cancer and COPD (R01) DHHS – NIH RFA-HL-11-002

Description: This Funding Opportunity Announcement (FOA) issued by the National Heart, Lung, and Blood Institute and the National Cancer Institute, National Institutes of Health, solicits Research Project Grant (R01) applications from institutions/organizations to identify the fundamental etiopathogenetic commonalities between lung cancer and Chronic Obstructive Pulmonary Disease (COPD) in order to characterize:

- (a) the genotypic and phenotypic characteristics that determine individual susceptibility; and
- (b) the shared biochemical, molecular, and immunological pathways involved in the origin and progression of the two diseases.

This FOA will utilize the Research Project Grant (R01) award mechanism. The NHLBI intends to commit up to \$12,000,000 (Total Costs) and the NCI intends to commit up to \$12,000,000 (Total Costs) over 4 years. It is anticipated that up to 8 awards will be made.

Link to Full Announcement:

<http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-11-002.html>

Opportunity #9

DoD Neurofibromatosis Exploration – Hypothesis Development Award Department of Defense - Dept. of the Army -- USAMRAA W81XWH-10-NFRP-EHDA

Description: The NFRP Exploration – Hypothesis Development Award (EHDA) mechanism was first offered in FY08. Since that time, 46 EHDA applications have been received, and 13 have been recommended for funding. The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the neurofibromatosis and/or Schwannomatosis research fields. Results of studies conducted through this award may provide the scientific rationale upon which a new hypothesis can be based, or they should provide initial principles of an innovative hypothesis. This award is designed to provide investigators with the opportunity to pursue serendipitous observations. The presentation of preliminary data is encouraged, but not required. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate how the proposed research is innovative and how the concept is novel. DOD FY10 Neurofibromatosis Exploration – Hypothesis Development Award 3. Because these awards are designed for preliminary investigations, projects involving human subjects or specimens will not be supported unless they are exempt under 32 CFR 219.101(b) or eligible for expedited review (32 CFR 219.110 or 21 CFR 56.110). Additional information on the protection of human subjects and exempt or expedited review status may be found at

[https://www.bids.tswg.gov/TSWG/bids.nsf/5DD5E2BA50F02C18852572B1005F5B8B/\\$file/Title_32_CFR_Part_219.pdf](https://www.bids.tswg.gov/TSWG/bids.nsf/5DD5E2BA50F02C18852572B1005F5B8B/$file/Title_32_CFR_Part_219.pdf). Applications proposing studies that do not qualify for exempt or expedited review status will be administratively withdrawn. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. Areas of Encouragement: The FY10 NFRP encourages research proposals that specifically address the critical needs of the NF community in the following areas:

- Complications of NF with high mortality such as neoplasms and cerebrovascular abnormalities;
- Complications of NF with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects, and pain;
- Refinement and standardization of imaging techniques, molecular and cellular markers, and quality of life metrics for use in future clinical trials; and
- Translational research such as the development or preclinical testing of therapeutic agents for the treatment of NF.

Link to Full Announcement:

<http://www07.grants.gov/search/announce.do;jsessionid=yskPLThYrSd1vPpkR1hGLPzTdyxpZQmr2tByyFVv7xnQkySJD94Z!117535442>

Opportunity #10

DoD Prostate Cancer Health Disparity Research Award Department of Defense - Dept. of the Army -- USAMRAA W81XWH-10-PCRP-HDRA

Description: The PCRP Health Disparity Research Award mechanism was introduced in FY01. Since then, 177 applications have been received, and 45 have been recommended for funding. In FY09, through a Request for Information (RFI), the PCRP solicited feedback from the prostate cancer research community on critical needs to facilitate prostate cancer health disparity research. This award mechanism has been modified for FY10 in response to the RFI feedback received. The Health Disparity Research Award supports new ideas that represent innovative approaches to prostate cancer health disparity research with the potential to make an important contribution to eliminating death and suffering from prostate cancer. The Health Disparity Research Award reflects the PCRP's commitment to resolving disparities in prostate cancer incidence, morbidity, and mortality by funding health disparity-focused projects. Studies proposed for this award mechanism are expected to improve the understanding of, and ultimately eliminate, health disparities. Applicants for this award must explicitly state how the proposed research is related to an area of prostate cancer health disparity. Appropriate health disparity areas include, but are not limited to, race and ethnicity, socioeconomic status, access to health care, insurance status, age, geography, and cultural beliefs. Due to this award's emphasis on innovation, presentation of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Any preliminary data provided should be from the laboratory of the Principal Investigator (PI) or member(s) of the collaborating team. Research involving human subject use is permitted under this funding opportunity, but is restricted to studies without clinical trials. In general, a clinical trial is defined as a prospective study where an intervention (e.g., device, drug, behavioral, surgical procedure, or other) is tested on human subjects for a measurable outcome. Refer to the General Application Instructions, Appendix 5, for additional information about studies involving human subjects, human subjects data, or human anatomical substances. The PCRP seeks Health Disparity Research Award applications from the wide spectrum of basic to clinical research (excluding clinical trials). Applications must be responsive to at least one of the PCRP focus areas and, although not required, may also be responsive to the PCRP overarching challenges. PIs wishing to apply for funding for population-based studies may also consider submitting an application for the PCRP Population-Based Research Award; each research project may be submitted to only one award mechanism. New for FY10! The following components of the Health Disparity Research Award are new for this fiscal year:

1. **Qualified Collaborator Option:** The FY10 Health Disparity Research Award strongly supports collaborative research between basic and clinical researchers, between researchers with prostate cancer expertise and those with health disparity expertise, and between researchers and community organizations that may be critical to the study of populations disproportionately affected by prostate cancer. Although these and other types of collaboration are, in general, strongly encouraged, collaborations that meet DOD FY10 Prostate Cancer Health Disparity Research Award 4 specific criteria will qualify for a higher level of funding as described in Section I.D., Funding. For the application to qualify for a higher level of funding, the PI must submit a Qualified Collaboration Statement that clearly describes the collaborator and addresses how each of the criteria below are met. In addition, the collaborator must provide a letter of collaboration describing his/her involvement in the proposed work. It should be clear that the success of the project depends on the unique skills and contributions of both the PI and the qualified collaborator. The following criteria must be met to use the Qualified Collaborator Option:
 - The collaborator must significantly contribute to the project such that the proposed work could not be accomplished without his/her involvement. This is expected to include both intellectual input and research resources (e.g., supplies, reagents, equipment, personnel, services, tissue samples, or access to patients).
 - The collaborator must contribute at least a 10% level of effort to the project. Contribution of the collaborator should be reflected in the application budget.
 - If the PI does not have experience in prostate cancer research or working with disproportionately affected populations, the collaborator must possess such experience.
2. **New Investigator Option:** The FY10 Health Disparity Research Award mechanism encourages applications from investigators in the early stages of their careers. The New Investigator Option is designed to allow applicants, early in their faculty appointments or in the process of developing independent research careers, to compete for funding separately from established investigators. Applications from New Investigators and Established Investigators will be peer and programmatically reviewed in separate groups. Applicants for the New Investigator Option are strongly encouraged to strengthen their applications by including investigators experienced in prostate cancer research and/or other relevant expertise as demonstrated by a record of funding and publications. It is the responsibility of the applicant to describe how additional investigators will augment the PI's expertise and better address the research question. Applicants for the New Investigator Option are permitted to also use the Qualified Collaborator Option. All applicants for the New Investigator Option must meet specific eligibility criteria as described in Section I.C., Eligibility.

3. Health Disparity Research Resources: Responses to the FY09 PCRFP RFI identified difficulties in establishing relevant collaborations and obtaining access to relevant study populations as major barriers to prostate cancer health disparity research. Therefore, potential applicants for the Health Disparity Research Award are encouraged to seek collaborations and access to appropriate study populations through the following resources:
- Congressionally Directed Medical Research Programs (CDMRP): Search the CDMRP awards database at <http://cdmrp.army.mil>. DOD FY10 Prostate Cancer Health Disparity Research Award 5
 - The North Carolina – Louisiana Prostate Cancer Project (PCaP): PCaP is supported by the PCRFP to conduct prostate cancer health disparity studies. PCaP members and institutions may be found at <http://www.ncla-pcap.org/>.
 - National Institutes of Health Research Portfolio Online Reporting Tool (NIH Reporter): Search for NIH awards at <http://projectreporter.nih.gov/reporter.cfm>.
 - Defense Technical Information Center (DTIC): Search for DOD and other government-funded investigators through DTIC Technical Reports at <http://www.dtic.mil/dtic/>
 - National Cancer Institute Center to Reduce Cancer Health Disparities (CRCHD): Search for health disparity research and researchers at <http://crchd.cancer.gov/disparities/disparities-index.html>
 - National Center on Minority Health and Health Disparities (NCMHD) Community Based Participatory Research (CBPR) Initiative: Contact the NCMHD at http://ncmhd.nih.gov/our_programs/CommunityParticipationResearch.asp for information on current CBPR programs, and scientists and communities engaged in health disparity research.
 - National Library of Medicine, National Institutes of Health, PubMed: Search for investigators publishing studies on prostate cancer health disparities at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=PubMed>.
 - U.S. Department of Education: Search for institutions that may have increased access to disproportionately affected populations at <http://www2.ed.gov/about/offices/list/ocr/edlite-minorityinst.html>

In addition, PIs are encouraged to establish and/or maintain interactions with organizations relevant to their proposed studies including the Urban League, National Medical Association, National Alliance for Hispanic Health, American Indian Health Care Association, National Rural Health Association, National African American Outreach Program of the Patient Advocate Foundation, Prostate Health Education Network, The Prostate Net, or other relevant organizations. It is the responsibility of the PI to clearly and explicitly articulate how the project addresses the following important aspects of the Health Disparity Research Award:

1. Research Question: Applications must clearly describe how the research question is relevant to an area of prostate cancer health disparity such as race and ethnicity, socioeconomic status, access to health care, insurance status, age, geography, and cultural beliefs.
2. Innovation: Research deemed innovative may represent a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. Innovative research may include high-risk approaches to prostate cancer health disparity research. Research that is an incremental advance upon published data is not considered innovative. DOD FY10 Prostate Cancer Health Disparity Research Award 6
3. Impact: Research that has high impact will, if successful, lead to significant reduction or elimination of the disproportionate effects of prostate cancer on specific populations and ultimately accelerate the overall elimination of death and suffering from prostate cancer.
4. Responsiveness to PCRFP focus areas and overarching challenges: Applications should describe the relevance of the proposed project to at least one of the PCRFP focus areas. Relevance to a PCRFP overarching challenge, if applicable, should also be described.

Link to Full Announcement:

<http://www07.grants.gov/search/search.do;jsessionid=yskPLThYrSd1vPpkR1hGLPzTdyxpZQmr2tByyFVv7xnQkySJD94Z!117535442?oppld=52289&mode=VIEW>

Opportunity #11

DoD Prostate Cancer Laboratory-Clinical Transition Award Department of Defense - Dept. of the Army -- USAMRAA W81XWH-10-PCR-P-LCTA

Description: The PCR-P Laboratory Clinical Transition Award mechanism was introduced in FY07. Since then, 36 applications have been received, and 6 have been recommended for funding. The Laboratory Clinical Transition Award supports goal- and product-driven preclinical studies of promising lead agents that have the potential to revolutionize prostate cancer clinical care. This award is intended to fund PIs who lack support to conduct the preclinical studies needed to advance lead agents to human testing. The goal of this award is the generation of pharmacology and toxicology data for inclusion in a U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application prior to current Good Manufacturing Practice (cGMP) production of the lead agent(s). Agents supported by this award mechanism are expected to have high potential for commercial licensing for continued development and clinical use. Applicants are expected to have a validated target, and to have identified either one lead agent or a limited number of lead agents for optimization before applying for this award. In addition, the PI should present data establishing the mechanism of action of the lead agent(s) on the target. Lead agents are defined as novel biological, molecular, or chemical therapeutics or imaging agents, that have potential clinical application to prostate cancer. Examples of lead agents include, but are not limited to: novel chemotherapeutics, antibodies, nanoparticles, and imaging contrast agents. Proposals must include preliminary data relevant to the lead agent(s) under development. Preliminary data must document target availability and distribution in relevant human tissues, and must provide substantive information from model systems that supports the potential efficacy of the lead agent(s) in humans. The National Cancer Institute (NCI) has constructed developmental pathways for translational research that may be useful for designing translational research studies for support under this mechanism. These pathways are comprehensive and span the entire translational research continuum from discovery of a target to clinical trials (http://www.cancer.gov/images/trwg/Developmental-Pathway-Agent-Drug_Biologics.pdf). Please note that the focus of this award is to support the development of the lead agent(s) up to but not including cGMP production of the agent. Studies proposed under this award may include, but are not limited to:

- Comparative activity/efficacy testing to optimize a lead agent and/or define a single lead agent from a limited library of candidates. Such studies must be completed within 12 months of the start date of the award. If the studies are not completed within 12 months of award initiation, the government reserves the right to terminate the award.
- Toxicology screening
- Pharmacokinetics (e.g., absorption, distribution, metabolism, and excretion) studies
- Pharmacodynamic studies
- Radiation dosimetry DOD FY10 Prostate Cancer Laboratory-Clinical Transition Award 4
- Development and validation of assays and reagents required to measure biological responses and molecular endpoints of the lead agent; such studies may only be proposed in conjunction with lead agent development
- Combination of the lead agent with agents already in clinical testing or practice Studies proposed under this award should not include:
 - Target discovery
 - Drug screening
 - Development of devices
 - New combinations, formulations, or modifications of agents already in clinical testing or practice (other than in combination with the lead agent)
 - Mechanism of action studies
 - Prevention agents Projects involving human subjects or specimens will be supported only if they are exempt under Title 32 of the Code of Federal Regulations Section 219.101(b) (4) (32 CFR 219.101(b) (4)) or qualify for expedited review under 32 CFR 219.110 or 21 CFR 56.1102. Clinical trials are not allowed. In general, a clinical trial is defined as a prospective study where an intervention (e.g., device, drug, behavioral, surgical procedure, or other) is tested on human subjects for a measurable outcome. Additional information on the protection of human subjects and exempt or expedited review status may be found at [https://www.bids.tswg.gov/TSWG/bids.nsf/5DD5E2BA50F02C18852572B1005F5B8B/\\$file/Title_32_CFR_Part_219.pdf](https://www.bids.tswg.gov/TSWG/bids.nsf/5DD5E2BA50F02C18852572B1005F5B8B/$file/Title_32_CFR_Part_219.pdf).

Applications proposing studies that do not qualify for exempt or expedited review status will be administratively withdrawn. The preclinical drug development process may require resources beyond those available at a single laboratory or organization. As such, the PI must disclose any patents issued or pending, and/or licenses granted and/or pending, with respect to the lead agent(s) as well as any known patents that may block the development of the lead agent(s). The PI must provide documentation, such as a Material Transfer Agreement, of access to and permission to use all intellectual and material property. Participating organizations must be willing to resolve potential

intellectual and material property issues, and to remove organizational barriers that might interfere with the cooperation necessary to ensure that the proposed studies can be completed. PIs are expected to abide by the FDA existing and proposed guidances governing the conduct of preliminary studies and the collection of data in support of an IND application (refer to http://www.fda.gov/cder/regulatory/applications/ind_page_1.htm). Applications must describe statistical analyses to support the proposed studies. Statistical analyses must be consistent with current FDA guidance.

Link to Full Announcement:

<http://www07.grants.gov/search/announce.do;jsessionid=yskPLThYrSd1vPpkR1hGLPzTdyxpZQmr2tByyFVv7xnQkySJD94Z!117535442>

Opportunity #12

DoD Prostate Cancer Population-Based Research Award Department of Defense - Dept. of the Army -- USAMRAA W81XWH-10-PCRP-PBRA

Description: The PCRP Population-Based Research Award mechanism was first offered as the Population-Based Idea Development Award in FY09. Thirty-one applications were received, and none were recommended for funding. The award mechanism has been modified for FY10. The FY10 Population-Based Research Award mechanism supports high-impact, population-based approaches to prostate cancer research. These studies, if successful, should contribute significantly to the elimination of death and suffering from prostate cancer. Proposed research must be responsive to at least one of the FY10 PCRP overarching challenges and at least one of the focus areas. The overall goal of this award is to generate unique information and/or tools that can only be achieved from the perspective of statistical analysis of a defined patient population. Applications may propose retrospective, prospective, case control, cohort, or other population-based study designs, provided the population sample is of sufficient size to demonstrate statistical significance. The study should address a well developed hypothesis that is conceptually sound and specific for prostate cancer. The statistical expertise of the study team should be clearly described and evident in the study plan. It is expected that investigators will demonstrate appropriate access to the population(s) needed for the study. Research proposed under the Population-Based Research Award may include the following areas:

- Biomarkers
- Predictors of response to therapy
- Disease aggressiveness
- Epidemiology
- Genomics (germline or somatic)
- Health disparity
- Molecular genetics
- Risk prediction

Research involving human subject use is permitted under this funding opportunity, but is restricted to studies without clinical trials. In general, a clinical trial is defined as a prospective study where an intervention (e.g., device, drug, behavioral, surgical procedure, or other) is tested on human subjects for a measurable outcome. Refer to the General Application Instructions, Appendix 5, for additional information about studies involving human subjects, human subjects data, or human anatomical substances. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate how the project addresses the following important aspects of the Population-Based Research Award:

1. Impact: Research that has high impact will, if successful, significantly accelerate the elimination of death and suffering from prostate cancer.
2. Statistical plan: A robust statistical plan is required and should be supported with requisite statistical expertise in the study team. DOD FY10 Prostate Cancer Population-Based Research Award 4
3. Human subject plan: Applicants should provide documentation demonstrating access to, and ability to recruit, the appropriate population(s) or patient samples in numbers sufficient to achieve statistical significance.
4. Preliminary data: The presentation of preliminary data to support the study feasibility is required. Any preliminary data provided should be from the laboratory of the PI or member(s) of the collaborating team.
5. Responsiveness to PCRP overarching challenges and focus areas: The relevance of the research problem to at least one of the PCRP overarching challenges and at least one of the PCRP focus areas.

Link to Full Announcement:

<http://www07.grants.gov/search/announce.do;jsessionid=yskPLThYrSd1vPpkR1hGLPzTdyxpZQmr2tByyFVv7xnQkySJD94Z!117535442>

Opportunity #13

DoD Tuberous Sclerosis Complex Career Transition Award Department of Defense - Dept. of the Army -- USAMRAA W81XWH-10-TSCR-CARTA

Description: The TSCR Career Transition Award (CARTA) mechanism was first offered in FY08. Since that time, 9 CARTA applications have been received, and 2 have been recommended for funding. The CARTA supports TSC researchers during the transition from postdoctoral training to an independent position. This award will cover up to two years of postdoctoral training followed by up to two years of a faculty-level position. Under this award mechanism, the postdoctoral candidate is considered the Principal Investigator (PI). DOD FY10 Tuberous Sclerosis Complex Career Transition Award 3 Important aspects of this award are as follows:

- The award covers the last two years of a postdoctoral fellowship and the first two years of an independent faculty position.
- Career transition and development plans must be clearly articulated.
- A mentor must be named who will support and guide the PI during the postdoctoral period of the award.
- All applications must include preliminary data relevant to TSC research and the proposed project.

Clinical trials are not allowed under this award mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Research Award mechanism.

Link to Full Announcement:

<http://www07.grants.gov/search/announce.do;jsessionid=yskPLThYrSd1vPpkR1hGLPzTdyxpZQmr2tByyFVv7xnQkySJD94Z!117535442>